| 1 |
33063648 | Molecular dynamic mechanism(s) of inhibition of bioactive antiviral phytochemical compounds targeting cytochrome P450 3A4 and P-glycoprotein. | 2022 Feb |
1 |
| 2 |
33464545 | Effect of Food on the Pharmacokinetics of the Oral Docetaxel Tablet Formulation ModraDoc006 Combined with Ritonavir (ModraDoc006/r) in Patients with Advanced Solid Tumours. | 2021 Mar |
1 |
| 3 |
33536797 | Pharmacokinetics and Toxicities of Oral Docetaxel Formulations Co-Administered with Ritonavir in Phase I Trials. | 2021 |
1 |
| 4 |
33649517 | Investigating the influence of relevant pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of orally administered docetaxel combined with ritonavir. | 2021 Jun |
1 |
| 5 |
33709626 | ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration-resistant prostate cancer patients: A phase Ib study. | 2021 Aug |
1 |
| 6 |
33759544 | Predictive association of ABCB1 C3435T genetic polymorphism with the efficacy or safety of lopinavir and ritonavir in COVID-19 patients. | 2021 Apr |
1 |
| 7 |
33312066 | Pharmacogenomics landscape of COVID-19 therapy response in Serbian population and comparison with worldwide populations. | 2020 Oct 2 |
2 |
| 8 |
31481446 | Anti-HIV and Anti-Hepatitis C Virus Drugs Inhibit P-Glycoprotein Efflux Activity in Caco-2 Cells and Precision-Cut Rat and Human Intestinal Slices. | 2019 Nov |
2 |
| 9 |
31696528 | Pharmacokinetics and Placental Transfer of Bupivacaine Enantiomers in HIV-Infected Parturient Women on Antiretroviral Therapy. | 2019 Nov 6 |
1 |
| 10 |
29649076 | Pharmacokinetics of Tenofovir Alafenamide When Coadministered With Other HIV Antiretrovirals. | 2018 Aug 1 |
2 |
| 11 |
29869311 | Generation of a Weakly Acidic Amorphous Solid Dispersion of the Weak Base Ritonavir with Equivalent In Vitro and In Vivo Performance to Norvir Tablet. | 2018 Jul |
2 |
| 12 |
30098863 | HIF-1α-induced xenobiotic transporters promote Th17 responses in Crohn's disease. | 2018 Nov |
2 |
| 13 |
28848011 | Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran. | 2017 Nov |
1 |
| 14 |
28901962 | Ability of polymer-bound P-glycoprotein inhibitor ritonavir to overcome multidrug resistance in various resistant neuroblastoma cell lines. | 2017 Nov |
3 |
| 15 |
27747723 | Postoperative Bleeding After Administration of a Single Dose of Rivaroxaban to a Patient Receiving Antiretroviral Therapy. | 2015 Dec |
1 |
| 16 |
24212378 | In vitro predictability of drug-drug interaction likelihood of P-glycoprotein-mediated efflux of dabigatran etexilate based on [I]2/IC50 threshold. | 2014 Feb |
2 |
| 17 |
24399452 | Pharmacokinetic drug interactions of afatinib with rifampicin and ritonavir. | 2014 Mar |
1 |
| 18 |
24648507 | Low-density lipoprotein and ritonavir: an interaction between antiretrovirals and lipids mediated by P-glycoprotein. | 2014 Jul |
3 |
| 19 |
24997317 | Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. | 2014 Nov |
1 |
| 20 |
25151207 | Single-nucleotide polymorphisms in the UDP-glucuronosyltransferase 1A-3' untranslated region are associated with atazanavir-induced nephrolithiasis in patients with HIV-1 infection: a pharmacogenetic study. | 2014 Dec |
1 |
| 21 |
23305158 | Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. | 2013 Sep |
1 |
| 22 |
23341120 | The antiretroviral protease inhibitor ritonavir accelerates glutathione export from cultured primary astrocytes. | 2013 Apr |
1 |
| 23 |
23892274 | Pharmacokinetic interactions between 20(S)-ginsenoside Rh2 and the HIV protease inhibitor ritonavir in vitro and in vivo. | 2013 Oct |
1 |
| 24 |
24014652 | Lack of P-glycoprotein-mediated efflux and the potential involvement of an influx transport process contributing to the intestinal uptake of deltamethrin, cis-permethrin, and trans-permethrin. | 2013 Dec |
2 |
| 25 |
20147896 | A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. | 2010 Jun |
1 |
| 26 |
20197013 | Effect of saquinavir/ritonavir on P-glycoprotein activity in healthy volunteers using digoxin as a probe. | 2010 Mar |
5 |
| 27 |
20551216 | Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines. | 2010 Aug |
3 |
| 28 |
18855943 | Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line. | 2009 Mar |
1 |
| 29 |
19207033 | ABCB1 polymorphisms and the concentrations of lopinavir and ritonavir in blood, semen and saliva of HIV-infected men under antiretroviral therapy. | 2009 Feb |
1 |
| 30 |
19960055 | Functional role of p-glycoprotein and binding protein effect on the placental transfer of lopinavir/ritonavir in the ex vivo human perfusion model. | 2009 |
2 |
| 31 |
18183034 | Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients. | 2008 Jul |
2 |
| 32 |
18285477 | Effect of low-dose ritonavir on the pharmacokinetics of the CXCR4 antagonist AMD070 in healthy volunteers. | 2008 May |
2 |
| 33 |
18646322 | P-glycoprotein expression in HTLV-III cells after treatment with HIV-1 protease inhibitors. | 2008 Spring |
1 |
| 34 |
19238656 | Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities. | 2008 Oct |
3 |
| 35 |
17148966 | Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. | 2007 Jan 2 |
1 |
| 36 |
17517050 | Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients. | 2007 Sep |
1 |
| 37 |
17048292 | P-glycoprotein effects of cyclic urea HIV protease inhibitor DMP 323 in competitional absorption studies. | 2006 Nov |
1 |
| 38 |
15764714 | Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. | 2005 Jun |
1 |
| 39 |
14985144 | Ritonavir and dexamethasone induce expression of CYP3A and P-glycoprotein in rats. | 2004 Feb |
4 |
| 40 |
15040543 | Intracellular accumulation of nelfinavir and its relationship to P-glycoprotein expression and function in HIV-infected patients. | 2004 Feb |
1 |
| 41 |
15167636 | Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes. | 2004 Jun |
6 |
| 42 |
15229466 | Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. | 2004 Jul |
4 |
| 43 |
15266218 | In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity. | 2004 Jul-Aug |
1 |
| 44 |
15553233 | Comparative effects on intestinal absorption in situ by P-glycoprotein-modifying HIV protease inhibitors. | 2004 Oct |
1 |
| 45 |
12714803 | Differential effect of HIV-1 protease inhibitors on P-glycoprotein function in multidrug-resistant variants of the human CD4+ T lymphoblastoid CEM cell line. | 2003 May |
2 |
| 46 |
12824804 | Digoxin toxicity and ritonavir: a drug interaction mediated through p-glycoprotein? | 2003 Jul 4 |
1 |
| 47 |
12902797 | The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro. | 2003 Aug 15 |
1 |
| 48 |
12948013 | Quantitative evaluation of the function of small intestinal P-glycoprotein: comparative studies between in situ and in vitro. | 2003 Aug |
1 |
| 49 |
12948015 | Rapid assessment of P-glycoprotein inhibition and induction in vitro. | 2003 Aug |
2 |
| 50 |
14525546 | Saquinavir induces stable and functional expression of the multidrug transporter P-glycoprotein in human CD4 T-lymphoblastoid CEMrev cells. | 2003 Oct |
2 |